Abstract:Abstract Relapse remains a formidable challenge for acute lymphoblastic leukemia (ALL). Recently, recurrent mutations in NT5C2 were identified as a common genomic lesion unique in relapsed ALL and were linked to acquired thiopurine resistance. However, molecular mechanisms by which NT5C2 regulates thiopurine cytotoxicity were incompletely understood. To this end, we sought to comprehensively characterize the biochemical and cellular effects of NT5C2 mutations. Compared with wild-type NT5C2, mutant proteins showed elevated 5′-nucleotidase activity with a stark preference of thiopurine metabolites over endogenous purine nucleotides, suggesting neomorphic effects specific to thiopurine metabolism. Expression of mutant NT5C2 mutations also significantly reduced thiopurine uptake in vitro with concomitant increase in efflux of 6-mercaptopurine (MP) metabolites, plausibly via indirect effects on drug transporter pathways. Finally, intracellular metabolomic profiling revealed significant shifts in nucleotide homeostasis induced by mutant NT5C2 at baseline; MP treatment also resulted in global changes in metabolomic profiles with completely divergent effects in cells with mutant versus wild-type NT5C2. Collectively, our data indicated that NT5C2 mutations alter thiopurine metabolism and cellular disposition, but also influence endogenous nucleotide homeostasis and thiopurine-induced metabolomic response. These complex mechanisms contributed to NT5C2-mediated drug resistance in ALL and pointed to potential opportunities for therapeutic targeting in relapsed ALL.

Supplementary Figures 1-5 from Mechanisms of &Lt;i>nt5c2</i>-Mediated Thiopurine Resistance in Acute Lymphoblastic Leukemia

Supplemetal Data from Genetic Ablation of Rbm38 Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

Mechanisms of <i>NT5C2</i>-Mediated Thiopurine Resistance in Acute Lymphoblastic Leukemia

Mechanisms of NT5C2-mediated thiopurine resistance in acute lymphoblastic leukemia.

Supplementary Materials and Methods, Supplementary Figure Legends, and Supplementary Table from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Supplementary Figure 1 from UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy Against Acute Lymphoblastic Leukemia <i>in Vitro</i> and <i>in Vivo</i>

Supplementary Figure 1 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Supplementary Methods and Figure S1-S12 from Mutant U2AF1-Induced Mis-Splicing of Mrna Translation Genes Confers Resistance to Chemotherapy in Acute Myeloid Leukemia

Supplementary Figure S4 from Combination Therapy Targeting Ribosome Biogenesis and Mrna Translation Synergistically Extends Survival in MYC-Driven Lymphoma

Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Supplementary Figure S3 from Combination Therapy Targeting Ribosome Biogenesis and Mrna Translation Synergistically Extends Survival in MYC-Driven Lymphoma

Supplementary Figure Legends from Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor

Supplementary Figure Legends 1-5 from Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis

Supplementary Figures from METTL1-Mediated m<sup>7</sup>G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma

Supplementary Figures from Characterization of Endogenous Human Promyelocytic Leukemia Isoforms

Figures S7 - S9 from Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma

Supplementary Figure 4 from Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia

Supplementary Figure 6 from Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells Against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia

Supplementary Table S1-S20 from Mutant U2AF1-Induced Mis-Splicing of mRNA Translation Genes Confers Resistance to Chemotherapy in Acute Myeloid Leukemia

Supplementary Tables from Mutational Landscape and Patterns of Clonal Evolution in Relapsed Pediatric Acute Lymphoblastic Leukemia

Supplementary Figures 1-5 from Mechanisms of &Lt;i&gt;nt5c2&lt;/i&gt;-Mediated Thiopurine Resistance in Acute Lymphoblastic Leukemia